Newswise — Although the most basic definition of a “theranostic” nanoparticle is a nanoparticle that simply has a therapeutic moiety and imaging or diagnostic moiety on the same particle, the authors of a new SLAS Technology review article pay particular attention to and emphasize the platforms in which self-reporting and disease monitoring is possible in real-time through the synergistic nature of the components on the theranostic particles.
The review is organized into theranostic nanoparticles of specific imaging and diagnostic modalities, including optical imaging, magnetic resonance imaging (MRI), ultrasound, computed tomography (CT), and nuclear imaging.
The evolving nature of the field toward such responsive and “smart” theranostic nanoparticles can be used as tools for life sciences researchers, especially in the context of identifying markers and characterizing cells and diseases over the course of its lifetime.
Many clinical imaging technologies have limitations in resolution when detecting small quantities of molecular markers, but theranostic nanoparticles can be used in combination to provide early detection and therapy of diseases, and has the potential to advance imaging platforms for improved performance.
Visit SLAS Technology Online at journals.sagepub.com/doi/full/10.1177/2472630317738698 to read Theranostic Nanoparticles for Tracking and Monitoring Disease State for free for a limited time. SLAS Technology is one of two PubMed:MEDLINE-indexed scientific journals published by SLAS. For more information about SLAS and its journals, visit www.slas.org/ journals.
Theranostic Nanoparticles for Tracking and Monitoring Disease State will be in place at journals.sagepub.com/doi/full/10.1177/2472630317738698 on Nov. 9. In the meantime, credentialed media representatives may contact Nan Hallock ([email protected]) for a PDF.
About our Society and Journals
SLAS (Society for Laboratory Automation and Screening) is an international community of nearly 20,000 professionals and students dedicated to life sciences discovery and technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.
SLAS DISCOVERY: 2016 Impact Factor 2.444. Editor-in-Chief Robert M. Campbell, Ph.D., Eli Lilly and Company, Indianapolis, IN (USA). SLAS Discovery (Advancing Life Sciences R&D) was previously published (1996-2016) as the Journal of Biomolecular Screening (JBS).
SLAS TECHNOLOGY: 2016 Impact Factor 2.850. Editor-in-Chief Edward Kai-Hua Chow, Ph.D., National University of Singapore (Singapore). SLAS Technology (Translating Life Sciences Innovation) was previously published (1996-2016) as the Journal of Laboratory Automation (JALA).
Follow SLAS on Twitter at @SLAS_Org.
Follow SLAS on Facebook at SocietyforLaboratoryAutomationandScreening.
Follow SLAS on YouTube at SLASvideo.
Follow SLAS Americas on LinkedIn at Society for Laboratory Automation and Screening (SLAS Americas).
Follow SLAS Europe on LinkedIn at Society for Laboratory Automation and Screening Europe (SLAS Europe).